



Press Release

## Cipla Strengthens its Focus on Biotech

~ Divests its remaining stake in Hong Kong based Biomab Holding to focus on global development under Cipla BioTec

**Mumbai, October 29, 2015:** Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced that it has entered into a definitive agreement to sell its entire 25% stake in Biomab Holding Limited, Hong Kong (“BHL”) to Biomab Brilliant Limited, British Virgin Islands which holds the remaining 75% stake in BHL, for a total consideration of USD 25,775,000.

Biomab Holding Limited is focused on developing Biosimilars for the Chinese market.

The closing of the transaction is subject to conditions precedent and receipt of applicable regulatory and other approvals.

Going forward, the Company’s biological business will be consolidated under Cipla BioTec. Cipla BioTec will focus on research, development, manufacturing and marketing of Biosimilars, in the field of cancer, auto-immune diseases, respiratory diseases and diabetes. Through innovative technology and go to market solutions, it aims to create a transformational impact in the way these medicines are used.

Chandru Chawla, Head of Cipla New Ventures said: “Cipla is seeing some very good momentum in its Biotech programs. Through Cipla BioTec we will focus on global product development with the aim of making biological therapies accessible and affordable to patients in need.”

### **About Cipla Limited**

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems.

**Media Contacts:**

**Corporate Communications**

Charlotte Chunawala

Mobile: +91 7506257377

E Mail: [charlotte.chunawala@cipla.com](mailto:charlotte.chunawala@cipla.com);

Pallavi Golar

Mobile: +91 9833641788

E Mail: [pallavi.golar@cipla.com](mailto:pallavi.golar@cipla.com)